Sign In
Buy EYPT
$12.25
-0.610 (-4.74%)
At Close: Jul 31, 2026
EyePoint to Report First Quarter 2026 Financial Results on May 6, 2026
07:00am, Wednesday, 29'th Apr 2026
WATERTOWN, Mass., April 29, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Insider Ramiro Ribeiro Sells 2,437 Shares of Stock
04:57am, Tuesday, 21'st Apr 2026
Eyepoint Pharmaceuticals, Inc. (NASDAQ: EYPT - Get Free Report) insider Ramiro Ribeiro sold 2,437 shares of Eyepoint Pharmaceuticals stock in a transaction on Friday, April 17th. The shares were sold
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
04:01pm, Thursday, 16'th Apr 2026
WATERTOWN, Mass., April 16, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with seriou
Aberdeen Group plc Has $29.34 Million Position in Eyepoint Pharmaceuticals, Inc. $EYPT
03:07am, Monday, 06'th Apr 2026
Aberdeen Group plc boosted its position in Eyepoint Pharmaceuticals, Inc. (NASDAQ: EYPT) by 101.6% in the undefined quarter, according to its most recent filing with the Securities and Exchange Commis
EyePoint Pharmaceuticals Teases August Phase 3 Wet AMD Data for DURAVYU at RBC Ophthalmology Conference
01:32am, Friday, 27'th Mar 2026
Executives from Eyepoint Pharmaceuticals (NASDAQ: EYPT) told investors at RBC Capital Markets' Ophthalmology Conference that the company's lead program, DURAVYU (vorolanib), is advancing through four
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
07:00am, Monday, 16'th Mar 2026
WATERTOWN, Mass, March 16, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious
This Biotech Stock Up Nearly 100% in a Year Has Drawn a New $20 Million Share Investment
07:05pm, Sunday, 15'th Mar 2026
Parkman bought 1,088,033 shares of EyePoint in the fourth quarter, marking a new stake for the fund. The quarter-end value of the EyePoint position increased by $19.88 million as a result.
Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Given Average Recommendation of “Buy” by Analysts
02:51am, Friday, 13'th Mar 2026
Eyepoint Pharmaceuticals, Inc. (NASDAQ: EYPT - Get Free Report) has been assigned an average recommendation of "Buy" from the eight ratings firms that are covering the company, Marketbeat reports. One
EyePoint, Inc. (EYPT) Q4 2025 Earnings Call Transcript
05:12pm, Wednesday, 04'th Mar 2026
EyePoint, Inc. (EYPT) Q4 2025 Earnings Call Transcript
EyePoint (EYPT) Reports Q4 Loss, Tops Revenue Estimates
09:20am, Wednesday, 04'th Mar 2026
EyePoint (EYPT) came out with a quarterly loss of $0.81 per share versus the Zacks Consensus Estimate of a loss of $0.78. This compares to a loss of $0.64 per share a year ago.
EyePoint Reports Fourth Quarter and Full-Year 2025 Financial Results and Highlights Recent Corporate Developments
07:00am, Wednesday, 04'th Mar 2026
– Both pivotal Phase 3 trials for DURAVYU in wet AMD on track for data readout beginning in mid-2026 – – Patients dosed in both COMO and CAPRI Phase 3 clinical trials for DURAVYU in DME – –
– Active Phase 3 programs for DURAVYU in wet AMD and DME, the two largest multi-billion-dollar retinal disease markets –
EyePoint to Report Fourth Quarter and Full-Year 2025 Financial Results on March 4, 2026
07:00am, Wednesday, 25'th Feb 2026
WATERTOWN, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with s
EyePoint Announces Participation at Upcoming Investor Conferences
07:00am, Tuesday, 24'th Feb 2026
WATERTOWN, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with s
EyePoint (EYPT) Surges 15.2%: Is This an Indication of Further Gains?
09:02am, Wednesday, 18'th Feb 2026
EyePoint (EYPT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
